MedTrace Logo

Zinc Supplementation in Type 2 Diabetics

NCT01309620 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-03-07

No results posted yet for this study

Summary

Zinc supplementation reduces the extent of oxidative damage and improves vascular indices in type 2 diabetics

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DIETARY_SUPPLEMENT

Zinc gluconate

Zinc gluconate (GNC, USA), 100 mg twice daily

DIETARY_SUPPLEMENT

Placebo

Placebo, Twice Daily

Sponsors & Collaborators

Principal Investigators

  • Raymond CS Seet, MBBS · National University Hospital, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-01-31
Completion
2010-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309620 on ClinicalTrials.gov